OptimizeRx (NASDAQ:OPRX) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Posted by Stanley Muller on May 14th, 2026

OptimizeRx (NASDAQ:OPRX – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13, FiscalAI reports. OptimizeRx had a net margin of 6.37% and a return on equity of 11.00%. The company had revenue of $19.84 million during the quarter, compared to the consensus estimate of $18.35 million.

Here are the key takeaways from OptimizeRx’s conference call:

OptimizeRx posted a solid Q1 fiscal 2026, with revenue of $19.8 million and adjusted EBITDA of $3.3 million, both above consensus expectations. GAAP net loss improved to $0.5 million from $2.2 million a year ago.
The company cut full-year 2026 revenue guidance to $95 million-$100 million from prior expectations, citing continued softness in contracted revenue, shorter client contract durations, and lingering macro/MFN-related budget caution. Management said visibility remains limited due to one large client with ongoing disruption.
Despite top-line pressure, OptimizeRx maintained adjusted EBITDA guidance of $21 million-$25 million and expects gross margin to normalize into the high 60% range. The company also highlighted cost actions expected to reduce cash operating expenses by about $3 million annually.
Growth in the company’s AI-enabled DAP solution remained strong, rising 60% in the quarter, while DAP subscription revenue grew 45%. Management said this shift toward subscription-based revenue should improve visibility and create a more durable business model.
OptimizeRx announced a major platform expansion that enables DSPs representing more than 80% of digital promotional dollars to connect directly to its authenticated EHR network. Management sees this as a potentially significant growth driver beginning in late 2026 and into 2027, with programmatic buying expected to lift inventory utilization over time.

OptimizeRx Price Performance

Shares of OPRX traded up $0.43 during trading hours on Thursday, reaching $5.34. 489,314 shares of the stock traded hands, compared to its average volume of 458,244. The company has a current ratio of 3.04, a quick ratio of 3.04 and a debt-to-equity ratio of 0.17. OptimizeRx has a 52-week low of $4.57 and a 52-week high of $22.25. The company’s 50-day moving average price is $6.54 and its two-hundred day moving average price is $10.83. The company has a market cap of $100.11 million, a P/E ratio of 15.19 and a beta of 1.19.

OptimizeRx declared that its board has authorized a share repurchase plan on Thursday, March 5th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the company to buy up to 6.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

Wall Street Analyst Weigh In

OPRX has been the subject of a number of research analyst reports. Lake Street Capital cut their target price on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday. Zacks Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 4th. Stephens cut their target price on shares of OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday. UBS Group set a $10.00 target price on shares of OptimizeRx in a research report on Wednesday. Finally, Roth Mkm cut their target price on shares of OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, OptimizeRx presently has an average rating of “Moderate Buy” and an average price target of $13.43.

View Our Latest Stock Analysis on OPRX

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OPRX. Barclays PLC lifted its stake in OptimizeRx by 18.7% in the 4th quarter. Barclays PLC now owns 27,441 shares of the company’s stock worth $336,000 after purchasing an additional 4,317 shares in the last quarter. GWN Securities Inc. purchased a new stake in OptimizeRx in the 4th quarter worth $274,000. Worth Venture Partners LLC purchased a new stake in OptimizeRx in the 3rd quarter worth $220,000. Creative Planning purchased a new stake in OptimizeRx in the 3rd quarter worth $331,000. Finally, Massar Capital Management LP purchased a new stake in OptimizeRx in the 2nd quarter worth $297,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

(Get Free Report)

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.